Publication | Closed Access

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Open-label TrialDiabetes ManagementCardiovascular DiseaseCardiovascular OutcomesMedicineDiabetesClinical TrialsCardiovascular PharmacologyOutcomes ResearchType 2PharmacotherapyDiabetes MellitusPharmacology